CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
5.93
+0.59 (11.05%)
Jan 27, 2026, 4:00 PM EST - Market closed
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover CytomX Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $8.00, which forecasts a 34.91% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $10.
Price Target: $8.00 (+34.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 3 |
| Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 5 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $6 → $8 | Buy | Maintains | $6 → $8 | +34.91% | Jan 20, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +68.63% | Jan 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $6.5 → $10 | Buy | Maintains | $6.5 → $10 | +68.63% | Jan 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $10 | Strong Buy | Maintains | $5 → $10 | +68.63% | Nov 11, 2025 |
| Barclays | Barclays | Buy Maintains $3.5 → $6 | Buy | Maintains | $3.5 → $6 | +1.18% | Oct 21, 2025 |
Financial Forecast
Revenue This Year
85.41M
from 138.10M
Decreased by -38.16%
Revenue Next Year
42.10M
from 85.41M
Decreased by -50.71%
EPS This Year
-0.02
from 0.38
EPS Next Year
-0.39
from -0.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 95.1M | 107.1M | ||||
| Avg | 85.4M | 42.1M | ||||
| Low | 77.9M | 3.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -31.2% | 25.4% | ||||
| Avg | -38.2% | -50.7% | ||||
| Low | -43.6% | -95.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.02 | -0.22 | ||||
| Avg | -0.02 | -0.39 | ||||
| Low | -0.06 | -0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -94.4% | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.